Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma

Acta Oto-Laryngologica

Volumn 128, Issue 7, 2008, Pages 808-813

  Nakashima, Masashi ^a   Kondo, Satoru ^a   Shimizu, Yoshinori ^a   Wakisaka, Naohiro ^a   Murono, Shigeyuki ^a   Furukawa, Mitsuru ^a   Yoshizaki, Tomokazu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Carcinogenesis; MDM2; Oncogene; p53; PCR

Indexed keywords

PROTEIN MDM2;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE SEQUENCE; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES;

EID: 45849100538     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480701724904     Document Type: Article

References (36)

1. Hanahan D, Weinberg RA. The hallmark of cancer. Cell 2000;100:57-70.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
4. Nylander K, Debelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2000;294:413-25.
5. Chen J, Wu X, Lin J, Levine AJ. Mdm-2 inhibits the G1 arrest and apoptosis of the p53 tumor suppressor protein. Mol Cell Biol 1996;16:2445-52.
6. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 1996;15:1596-606.
7. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 1998;17:2513-25.
8. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
9. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
10. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
11. Alhopuro P, Ylisaukko-oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, et al. The MDM2 promoter polymorphism SNP309T > G and the risk of uterine leiomysarcoma, colorectal cancer and squamous cell carcinoma of the head and neck. J Med Genet 2005;42:694-8.
12. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5104-10.
13. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 2006;43:950-2.
14. Freedman DA, Wu L, Levine J. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
15. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. Impact of the MDM2 SNP309 and TP53 Arg72Pro polymorphism on age of tumor onset in Li-Fraumeni syndrome. J Med Genet 2006;43:531-3.
16. Sotamaa K, Liyanarachchi S, Mecklin JP, Järvinen H, Aaltonen LA, Peltomäki P, et al. p53 codon and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-4.
17. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R, et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007;15:110-4.
18. Tabori U, Nanda S, Druker H, Lees J, Malkin D. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007;67:1415-8.
19. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposita G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
20. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434-40.
21. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582-7.
22. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006;119:718-21.
23. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006;12:4867-71.
24. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007;13:4123-9.
25. Onat OE, Tez M, Ozcelik T, Toruner GA. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 2006;26:3473-5.
26. Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 2007;13:3215-20.
27. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007;104:660-4.
28. Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, et al. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 2007;104:153-7.
29. Swinney RM, Hsu SC, Hirschman BA, Chen TT, Tomlinson GE. MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia 2005;19:1996-8.
30. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007;28:1996-2001.
31. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-7.
32. Zhou G, Zhai Y, Cui Y, Zhang X, Dong X, Yang H, et al. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 2007;13:2627-33.
33. Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006;240:195-7.
34. Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 2006;118:1275-8.
35. Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, et al. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:1559-61.
36. Park SH, Choi JE, Kim EJ, Jang JS, Han HS, Lee WK, et al. MDM2 309T > G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 2006;54:19-24.